- |||||||||| Humira (adalimumab) / Eisai, AbbVie
Antibiotic resistances in hidradenitis suppurative patients treated with adalimumab (Room 2) - Feb 2, 2023 - Abstract #EHSF2023EHSF_181; Otherwise, an empirical choice should be made. Future prospective studies on AB resistance patterns, microbiome characteristics and their relationships with different HS therapies, including AB, immunomodulatory drugs and anti-TNF-a targeted therapies, are required.
- |||||||||| Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Colonization by ceftazidime/avibactam-resistant KPC-producing Klebsiella pneumoniae following therapy in critically ill patients. (Pubmed Central) - Jan 31, 2023 Future prospective studies on AB resistance patterns, microbiome characteristics and their relationships with different HS therapies, including AB, immunomodulatory drugs and anti-TNF-a targeted therapies, are required. Antimicrobial exposure induce higher incidence of CAZ-AVI -resistance development in blood and respiratory tract than in rectum (6.7% vs 3.3%) of CAZ-AVI-treated patients and genome analysis showed that resistance was associated to mutated bla variants.
|